• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Israel·Healthcare·1696.HK
Share

Sisram Medical Ltd Stocks

HK$ 1.81Last Updated 02.11.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

HK$ 107.75M

HK$ 1.81
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Sisram Medical Ltd, an investment holding company headquartered in Caesarea, Israel, since its establishment in 2013, is engaged in the creation, production, and worldwide distribution of a broad spectrum of medical solutions. The company develops and markets energy-based aesthetic devices, minimally invasive therapeutic systems, non-energy-dependent equipment, and cosmeceuticals, reaching markets across Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. Its comprehensive range of products and treatments addresses numerous conditions, such as hair removal, skin revitalization, acne and scarring, body and facial sculpting, pigment and skin surface refinement, fat transfer procedures, injectable dermal fillers, skin tissue regeneration injectables, personal wellness items, cosmetic dental procedures, transdermal delivery methods, cellulite reduction, stretch mark amelioration, therapy for vascular and pigmented lesions, hydradermabrasion, non-surgical eyelid lifts (blepharoplasty), liposuction, as well as feminine health and sexual well-being applications. Furthermore, the company is involved in the manufacturing, distribution, and sales of general medical apparatus. Sisram Medical's offerings are available under its prominent brand names, which include Alma, Soprano, Harmony, Copulla, Foshion, Accent, and LMNT.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, undervalue

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

02.11.2026 16:18

Morning in New York: The High-Tech Sector Cools Off Ahead of the Election

02.11.2026 16:04

"I know he's an idiot": Ryanair CEO assesses the business benefits of his feud with Musk

02.11.2026 15:50

A "Cleaning-Out" Pullback: Morgan Stanley Suggests Entering the Market Ahead of a Rally to 8,000 Points

02.11.2026 15:10

"Some People Might Get Nervous": What Lies Ahead for the Tenge and Investors in Kazakh Bonds

02.11.2026 13:46

Goldman Sachs has raised its oil price forecast for 2027. What risks does the bank see?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026